AZACITIDINE
PYRIMIDINE ANALOGS·MYELODYSPLASTIC SYNDROME·+2
BLUEPOINT/ONCOP
Indication
Myelodysplastic syndrome
Myelodysplastic syndrome refers to a heterogeneous group of clonal hematopoietic stem cell neoplasms characterized by ineffective hematopoiesis, progressive peripheral blood cytopenias, and morphologic dysplasia across one or more blood cell lineages. Read more about Myelodysplastic syndrome
45 drugs 37 manufacturers
Drugs that treat it
Common Myelodysplastic syndrome therapies.
DECITABINE
PYRIMIDINE ANALOGS·MYELODYSPLASTIC SYNDROME
NOVADOZ-NOVAPLU
AZACITIDINE
PYRIMIDINE ANALOGS·MYELODYSPLASTIC SYNDROME·+2
MEITHEAL-NOVAPL
AZACITIDINE
PYRIMIDINE ANALOGS·MYELODYSPLASTIC SYNDROME·+2
Hikma Pharmaceuticals USA
DECITABINE
PYRIMIDINE ANALOGS·MYELODYSPLASTIC SYNDROME
Hikma Pharmaceuticals USA
DECITABINE
PYRIMIDINE ANALOGS·MYELODYSPLASTIC SYNDROME
FRESENIUS KABI
AZACITIDINE
PYRIMIDINE ANALOGS·MYELODYSPLASTIC SYNDROME·+2
CIVICA, INC.
AZACITIDINE
PYRIMIDINE ANALOGS·MYELODYSPLASTIC SYNDROME·+2
Pfizer Laboratories
DECITABINE
PYRIMIDINE ANALOGS·MYELODYSPLASTIC SYNDROME
BRYANT RANCH PR
Filter & compare in the drug finder →Opens the drug finder with Myelodysplastic syndrome preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMyelodysplastic syndrome refers to a heterogeneous group of clonal hematopoietic stem cell neoplasms characterized by ineffective hematopoiesis, progressive peripheral blood cytopenias, and morphologic dysplasia across one or more blood cell lineages.
Primarily affecting older adults, this hematologic disorder arises from acquired genetic or cytogenetic abnormalities within bone marrow progenitor cells that impair cellular maturation and survival.
Patients frequently present with fatigue, recurrent infections, or bleeding secondary to profound anemia, neutropenia, or thrombocytopenia.
Clinically, the syndrome exhibits variable risk of disease progression, carrying a substantial potential to transform into acute myeloid leukemia.
- nih.gov
Myelodysplastic syndrome refers to a heterogeneous group of clonal hematopoietic stem cell neoplasms characterized by ineffective hematopoiesis, progressive peripheral blood cytopenias, and morphologic dysplasia across one or more blood cell lineages Primarily affecting older adults, this hematologic disorder arises from acquired genetic or cytogenetic abnormalities within bone marrow progenitor cells that impair cellular maturation and survival Clinically, the syndrome exhibits variable risk of...
- nih.gov
Myelodysplastic syndrome refers to a heterogeneous group of clonal hematopoietic stem cell neoplasms characterized by ineffective hematopoiesis, progressive peripheral blood cytopenias, and morphologic dysplasia across one or more blood cell lineages Primarily affecting older adults, this hematologic disorder arises from acquired genetic or cytogenetic abnormalities within bone marrow progenitor cells that impair cellular maturation and survival Patients frequently present with fatigue, recurren...
- medlineplus.gov
Clinically, the syndrome exhibits variable risk of disease progression, carrying a substantial potential to transform into acute myeloid leukemia
Personalize your experience
Follow Myelodysplastic syndrome and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.